The phase 3 KEYNOTE-A39/EV-302 study has met its dual primary end points of overall survival (OS) and progression-free survival (PFS) in previously untreated, locally advanced or metastatic urothelial carcinoma (la/mUC), according to the latest topline results. The trial assessed the combination of enfortumab vedotin-ejfv (EV) plus pembrolizumab versus chemotherapy (gemcitabine plus cisplatin or carboplatin). Investigators enrolled patients who may or may not be eligible for treatment with cisplatin-based chemotherapy, regardless of PD-L1 status. ...
Advanced Urothelial Carcinoma
Advertisement
Latest News
Dr. de Kouchkovsky highlights survival and response rates after ICIs and EV for patients with squamous histology.
Dr. de Kouchkovsky explains studying the impact of squamous histology on clinical outcomes in mUC after ICIs or EV.
The positive results were consistent with findings from the primary analysis, such as PFS and overall response benefit.
Multiple genitourinary oncology therapies are in the spotlight this week, with new US FDA indications on the horizon.
Somatic alterations in DDR genes are common in patients with advanced urothelial cancer.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Dr. Gupta also discusses upcoming bladder cancer data from ESMO that will influence debate and discussion at the event.
Dr. Petros Grivas shares what data he's most looking forward to discussing at the second Uromigos: Live & Unplugged event.
The second annual Uromigos: Live & Unplugged event will take place in Nashville, Tennessee, on November 3-4.
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Advertisement
Section Editor
Vadim Koshkin, MDGenitourinary Medical Oncologist | University of California, San Francisco
Advertisement
Trending
The first PET scans using Illuccix, Telix’s PSMA-PET imaging agent, have been carried out in cooperation with BAMF Health.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
Few biomarkers predict therapeutic response to radiation or adjunctive treatments in PCa patients treated with radiotherapy.
